Effect of chemotherapy and aromatase inhibitors in the adjuvant treatment of breast cancer on glucose and insulin metabolism-A systematic review.


Journal

Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310

Informations de publication

Date de publication:
01 2019
Historique:
received: 27 09 2018
revised: 14 11 2018
accepted: 20 11 2018
pubmed: 19 12 2018
medline: 4 3 2020
entrez: 19 12 2018
Statut: ppublish

Résumé

Breast cancer (BC) is the most common cancer among women worldwide. With increasing survival rates, focus has expanded to long-term adverse effects of adjuvant chemotherapy and/or aromatase inhibitors. Weight gain during chemotherapy has been well documented, but the underlying mechanisms remain unclear. A change in glucose and insulin metabolism is a possible consequence. We searched PubMed on the 4th of May 2018, and found eight articles that compared measurements of glucose and insulin before and after chemotherapy and/or aromatase inhibitors in woman with BC. A general trend of increased glucose and insulin is seen and likely to be caused by weight gain and/or changes in body composition as a consequence of adjuvant treatment of BC. Due to methodological limitations including short follow-up times and small sample sizes, further studies are required to better describe metabolic consequences of adjuvant chemotherapy and/or aromatase inhibitors. Future studies could help identify patients in high-risk of developing cardiometabolic disease after BC treatment.

Identifiants

pubmed: 30561133
doi: 10.1002/cam4.1911
pmc: PMC6346263
doi:

Substances chimiques

Antineoplastic Agents 0
Aromatase Inhibitors 0
Insulin 0
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

238-245

Informations de copyright

© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Références

Breast Cancer Res Treat. 2015 Nov;154(1):127-32
pubmed: 26424165
Breast Cancer Res Treat. 2009 Apr;114(3):517-25
pubmed: 18437560
Pak J Pharm Sci. 2014 Sep;27(5 Spec no):1409-18
pubmed: 25176229
Oncol Nurs Forum. 1978 Jul;5(3):5-7
pubmed: 248815
Diabetologia. 2013 Mar;56(3):476-83
pubmed: 23238788
Am J Obstet Gynecol. 2005 Aug;193(2):347-51
pubmed: 16098853
J Vet Intern Med. 2017 Jul;31(4):1159-1162
pubmed: 28503759
Ann Epidemiol. 2016 Jun;26(6):436-40
pubmed: 27157863
Clin Nutr. 2014 Jun;33(3):550-7
pubmed: 24011971
Jpn J Clin Oncol. 2001 Sep;31(9):424-7
pubmed: 11689595
Breast Cancer Res Treat. 2007 Oct;105(2):177-86
pubmed: 17123151
J Cancer Surviv. 2012 Sep;6(3):305-14
pubmed: 22484807
Lung Cancer. 2016 Sep;99:131-6
pubmed: 27565928
Mol Clin Oncol. 2016 May;4(5):893-897
pubmed: 27123303
J Clin Oncol. 2001 May 1;19(9):2381-9
pubmed: 11331316
Cochrane Database Syst Rev. 2018 Jan 29;1:CD011292
pubmed: 29376559
Int J Obes Relat Metab Disord. 2001 Feb;25(2):296-8
pubmed: 11410835
Int J Womens Health. 2015 May 06;7:493-9
pubmed: 26005359
J Natl Cancer Inst. 2009 Apr 1;101(7):537
pubmed: 19318627
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Cancer. 1978 Apr;41(4):1590-4
pubmed: 639014
Breast Cancer Res Treat. 2018 Aug;170(3):455-476
pubmed: 29654416
J Clin Oncol. 1993 Jul;11(7):1418-29
pubmed: 8315439
Menopause. 2013 Apr;20(4):448-54
pubmed: 23149866
Br J Cancer. 2014 Oct 28;111(9):1836-42
pubmed: 25225901
Indian J Cancer. 2016 Jan-Mar;53(1):39-42
pubmed: 27146736
Arch Intern Med. 1991 Jan;151(1):97-102
pubmed: 1985614
J Cell Biochem. 2018 Mar;119(3):2923-2928
pubmed: 29120088
Diabetes. 1996 Jul;45(7):984-7
pubmed: 8666153
Am J Clin Nutr. 1997 Jul;66(1):141-6
pubmed: 9209182
Cancer. 2008 Jan 15;112(2):260-7
pubmed: 18041059
Obes Rev. 2012 Apr;13(4):368-80
pubmed: 22133030
PLoS One. 2016 Jun 16;11(6):e0157113
pubmed: 27310615
Crit Rev Oncol Hematol. 2018 Sep;129:54-66
pubmed: 30097238
Cancer Med. 2019 Jan;8(1):238-245
pubmed: 30561133
J Clin Oncol. 2015 Oct 1;33(28):3169-76
pubmed: 26282657
Am J Clin Nutr. 1997 May;65(5):1495-501
pubmed: 9129482
Curr Treat Options Oncol. 2015 May;16(5):22
pubmed: 25904412
BMJ. 2011 Jul 28;343:d4411
pubmed: 21798968
Breast Cancer Res Treat. 2015 Jun;151(3):569-76
pubmed: 25962694
Climacteric. 1999 Sep;2(3):205-11
pubmed: 11910598
Pharmacogenet Genomics. 2015 Aug;25(8):377-81
pubmed: 26049585
J Clin Oncol. 2018 Jul 10;36(20):2061-2069
pubmed: 29688833
Am J Epidemiol. 2004 Nov 1;160(9):912-22
pubmed: 15496544
J Clin Oncol. 2011 Jan 1;29(1):32-9
pubmed: 21115858
Cancer Nurs. 2014 Sep-Oct;37(5):355-62
pubmed: 24088604
Clin Breast Cancer. 2011 Mar;11(1):52-60
pubmed: 21421523
J Natl Cancer Inst. 2008 Feb 20;100(4):252-60
pubmed: 18270335
J Oncol Pharm Pract. 2016 Feb;22(1):46-53
pubmed: 25233884
J Clin Oncol. 1990 Aug;8(8):1327-34
pubmed: 2199619
Cancer. 2016 Sep 1;122(17):2646-53
pubmed: 27219902
Hormones (Athens). 2006 Apr-Jun;5(2):137-46
pubmed: 16807226
Am J Med. 2010 Jan;123(1):87.e1-6
pubmed: 20102997
JAMA Oncol. 2015 Dec;1(9):1311-8
pubmed: 26402167
Chemotherapy. 2016;61(2):57-64
pubmed: 26571369

Auteurs

Kristian Buch (K)

Diabetes and Bone-Metabolic Research Unit, Department of Endocrinology, Rigshospitalet, København Ø, Denmark.

Victoria Gunmalm (V)

Diabetes and Bone-Metabolic Research Unit, Department of Endocrinology, Rigshospitalet, København Ø, Denmark.

Michael Andersson (M)

Department of Oncology, Rigshospitalet, København Ø, Denmark.

Peter Schwarz (P)

Diabetes and Bone-Metabolic Research Unit, Department of Endocrinology, Rigshospitalet, København Ø, Denmark.
Faculty of Health Sciences, Copenhagen University, København N, Denmark.

Charlotte Brøns (C)

Diabetes and Bone-Metabolic Research Unit, Department of Endocrinology, Rigshospitalet, København Ø, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH